KRAS and Miyoshi myopathy: However, the mutations with a high prevalence in larger existing MM cohorts with NGS data such as those in the KRAS, NRAS, and TP53 genes were identified in the total BMA (eight validation cohort and fourteen clinical patients whose plasma cell enrichment failed) and blood samples (eight validation cohort) of patients using Piseq algorithm (Supplementary Table S5).